← Back to Companies

Sherlock Biosciences

Engineering biology company developing molecular diagnostic products using CRISPR-based SHERLOCK technology, enabling rapid, accurate, and accessible diagnostic testing for infectious diseases and other conditions.

Location
Cambridge, Massachusetts, USA
Founded
2019
Investors
1
Categories
diagnostics, molecular-diagnostics, crispr, engineering-biology, point-of-care

Notes

Sherlock Biosciences is a biotechnology company engineering biology to develop molecular diagnostic products that give people access to answers and more control over their health decisions. Founded in 2019 and headquartered in Cambridge, Massachusetts.

The company's core technology is SHERLOCK (Specific High-sensitivity Enzymatic Reporter unLOCKing), a CRISPR-based diagnostic platform that can detect specific nucleic acid sequences with high sensitivity and specificity. This technology enables:

  • Rapid point-of-care diagnostics
  • Infectious disease detection
  • Accessible testing without complex laboratory equipment

Sherlock Biosciences was founded by a team of world-renowned scientists and entrepreneurs, including pioneers of CRISPR technology.

Team

  • Rahul Dhanda - Co-founder & Chief Executive Officer
  • Jim Collins, Ph.D. - Co-founder (MIT Professor, MacArthur Fellow)
  • David Walt, Ph.D. - Co-founder (Harvard Professor)
  • Pardis Sabeti, M.D., D.Phil. - Co-founder (Harvard/Broad Institute)
  • Feng Zhang, Ph.D. - Scientific Advisor (Broad Institute, CRISPR pioneer)

Additional Research Findings

  • SHERLOCK CRISPR-based diagnostic platform
  • Point-of-care molecular diagnostics
  • Infectious disease detection focus
  • Cambridge, Massachusetts headquarters
  • Founded by leading CRISPR and diagnostics scientists
  • FDA-authorized COVID-19 diagnostic test

Sources

Investors

NameLocationTypeStagesPortfolio
Illumina VenturesSan Francisco, California, USAbiotech-focused
seedseries-a+1
32